Department of Health and Social Care -
The 2024 voluntary scheme for branded medicines pricing, access and growth is a voluntary agreement between the Department of Health and Social Care, NHS England and the Association of the British Pharmaceutical Industry. The voluntary scheme aims to: promote better patient outcomes and a healthier population; support UK economic growth; and contribute to a financially sustainable NHS. The 2024 voluntary scheme headline payment percentage for 2025 will be 22.9%. This document sets out how the level was set.
If you prefer to receive this content via email, you can sign up to our twice-weekly bulletin here: https://www.kingsfund.org.uk/emails
RSS feeds
All content
Changing configuration of health services
Commissioning
Competition and choice
Consultations
Developments in primary and community care
Equality and diversity
Integrated care
Leadership and leadership development
Local authorities, public health and health inequalities
Mental health
New technologies
NHS finances and productivity
NHS measurement and performance
Patient involvement, experience and feedback
Patient safety
Quality of care and clinical outcomes
Regulation, governance and accountability
Social care
Workforce and employment
Categories
- Brexit
- Commissioning
- Competition and choice
- Consultations
- Covid-19
- Digital health and data
- Environment and sustainability
- Equality and diversity
- General election
- Integrated care, collaboration and partnership
- Leadership and leadership development
- Legislation and reform
- Mental health
- NHS finance
- NHS performance and productivity
- Patient involvement, experience and feedback
- Patient safety
- Primary and community care
- Public health and health inequalities
- Quality of care and clinical outcomes
- Regulation, governance and accountability
- Social care
- Voluntary and community sector
- Workforce and employment